药物开发 药物开发
1Stanford University, Stanford, CA, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
概括
在阿尔茨海默氏病 (AD) 中,抑制p21激活激酶1 (PAK1) 在临床前模型中对突触脊柱损失进行了保护. 这表明PAK1抑制剂可能是阿尔茨海默病的潜在治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 突触退化,特别是树突性,是阿尔茨海默病 (AD) 的标志,与认知能力下降相关.
- 21激活激酶1 (PAK1) 是可菲林和动因动态的关键调节者,对突触脊柱完整性至关重要.
- 在AD中观察到PAK1失调,包括转移到细胞膜,并与认知障碍有关.
研究的目的:
- 研究抑制PAK1的治疗潜力,以防止阿尔茨海默病中突触脊柱损失.
- 测试该假设PAK1抑制可以赋予树突对粉样蛋白-β (Aβ) 和寡合体的弹性.
主要方法:
- 在体外研究中,小鼠海马神经元暴露在Aβ或tau寡合体中,有或没有选择性PAK1抑制剂NVS-PAK1-1.
- 在体内研究涉及口服NVS-PAK1-1给CD-1和5XFAD小鼠进行药理动力学-药理动力学 (PK-PD) 分析和树突脊柱量化.
- 测量PAK1活性是通过化PAK1 (pPAK1) 的西部涂抹测量.
主要成果:
- 在实验室中,NVS-PAK1-1证明了树突对Aβ和tau寡合物的显著保护 (EC50 = 1nM).
- 在5XFAD小鼠中,口服NVS-PAK1-1实现了治疗性脑度和剂量依赖的抑制PAK1活性.
- 用NVS-PAK1-1治疗使5XFAD小鼠的树突脊柱密度保持在与野生类型对照相比的水平上,而不会影响粉样蛋白水平.
结论:
- 在早期的AD模型中,PAK1的抑制提供了抗Aβ和tau病理的树突的弹性.
- 这些发现支持研究PAK1抑制剂作为阿尔茨海默病潜在治疗策略.
- 瘤学中PAK1抑制剂的现有临床试验可能有助于将其转化为AD治疗.
更多相关视频
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
3.3K
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
451
相关概念视频
Preclinical Development: Overview
5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview
10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview
1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation
279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
